Detail akcie Acarix Rg online

Business Summary: Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Acarix AB revenues increased 16% to SEK5.2M. Net loss decreased 27% to SEK36.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development costs decrease of 41% to SEK11.1M (expense), Sales, general and administrative costs decrease of 17% to SEK29.4M (expense).